NASDAQ:UTRS Minerva Surgical - UTRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Minerva Surgical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.38 +0.01 (+2.69%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.35▼$0.4050-Day Range$0.16▼$0.4352-Week Range$0.15▼$6.04Volume1.34 million shsAverage Volume2.99 million shsMarket Capitalization$11.37 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Minerva Surgical MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,211.0% Upside$5.00 Price TargetShort InterestHealthy4.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.20) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector178th out of 1,055 stocksSurgical & Medical Instruments Industry19th out of 106 stocks 3.0 Analyst's Opinion Consensus RatingMinerva Surgical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Minerva Surgical has a forecasted upside of 1,211.0% from its current price of $0.38.Amount of Analyst CoverageMinerva Surgical has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.44% of the float of Minerva Surgical has been sold short.Short Interest Ratio / Days to CoverMinerva Surgical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Minerva Surgical has recently decreased by 51.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Surgical does not currently pay a dividend.Dividend GrowthMinerva Surgical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for UTRS. Previous Next 4.1 News and Social Media Coverage News SentimentMinerva Surgical has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Minerva Surgical this week, compared to 0 articles on an average week.Search Interest4 people have searched for UTRS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows4 people have added Minerva Surgical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Surgical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.50% of the stock of Minerva Surgical is held by insiders.Percentage Held by Institutions65.05% of the stock of Minerva Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Minerva Surgical are expected to grow in the coming year, from ($1.20) to ($1.15) per share.Price to Book Value per Share RatioMinerva Surgical has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Minerva Surgical (NASDAQ:UTRS) StockMinerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.Read More Receive UTRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Surgical and its competitors with MarketBeat's FREE daily newsletter. Email Address UTRS Stock News HeadlinesJanuary 18, 2023 | seekingalpha.comUTRS Minerva Surgical, Inc.January 3, 2023 | finance.yahoo.comMinerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 29, 2022 | markets.businessinsider.comMinerva Surgical Appoints Todd Usen As CEO To Succeed David ClapperDecember 28, 2022 | finance.yahoo.comMinerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEODecember 28, 2022 | benzinga.comThinking about buying stock in Minerva Surgical, IQIYI, Cosmos Health, Acasti Pharma, or AMC Entertainment?December 28, 2022 | msn.comWhy Minerva Surgical Shares Are Up More Than 100% TodayDecember 28, 2022 | benzinga.comWhy Minerva Surgical Shares Are Trading Higher By 166%; Here Are 26 Stocks Moving PremarketJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 27, 2022 | finance.yahoo.comMinerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed PartnersNovember 24, 2022 | finanznachrichten.deMinerva Surgical, Inc.: Minerva Surgical Reports Third Quarter 2022 Financial ResultsNovember 21, 2022 | finance.yahoo.comMinerva Surgical to Present at the 34th Annual Piper Sandler Healthcare ConferenceNovember 16, 2022 | finance.yahoo.comMinerva Surgical Third Quarter 2022 Earnings: EPS Misses ExpectationsNovember 15, 2022 | seekingalpha.comMinerva Surgical, Inc. (UTRS) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finance.yahoo.comMinerva Surgical Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comMinerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference CallOctober 26, 2022 | finance.yahoo.comMinerva Surgical to Announce Third Quarter 2022 Financial ResultsAugust 29, 2022 | finance.yahoo.comMinerva Surgical to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 13, 2022 | seekingalpha.comMinerva Surgical, Inc. (UTRS) CEO Dave Clapper on Q2 2022 Results - Earnings Call TranscriptAugust 9, 2022 | finance.yahoo.comMinerva Surgical Reports Second Quarter 2022 Financial ResultsAugust 4, 2022 | finance.yahoo.comMinerva Surgical, Inc. (NASDAQ:UTRS) insider upped their holding by 4.0% earlier this yearAugust 3, 2022 | finance.yahoo.comMinerva Surgical Announces Time To Talk CampaignJuly 28, 2022 | finance.yahoo.comMinerva Surgical to Announce Second Quarter 2022 Financial ResultsJuly 21, 2022 | finance.yahoo.comMinerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of DirectorsJuly 3, 2022 | benzinga.comMinerva Surgical (NASDAQ:UTRS), Short Interest ReportJune 20, 2022 | finance.yahoo.comIs There An Opportunity With Minerva Surgical, Inc.'s (NASDAQ:UTRS) 43% Undervaluation?May 15, 2022 | seekingalpha.comMinerva Surgical, Inc. (UTRS) CEO David Clapper on Q1 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UTRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Surgical and its competitors with MarketBeat's FREE daily newsletter. Email Address UTRS Company Calendar Last Earnings11/14/2022Today1/31/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UTRS CUSIPN/A CIK1452965 Webwww.minervasurgical.com Phone855-646-7874FaxN/AEmployees157Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+1,211.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,460,000.00 Net Margins-34.03% Pretax Margin-34.01% Return on Equity-51.99% Return on Assets-17.35% Debt Debt-to-Equity Ratio1.82 Current Ratio2.14 Quick Ratio1.40 Sales & Book Value Annual Sales$52.10 million Price / Sales0.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.25Miscellaneous Outstanding Shares29,820,000Free Float27,282,000Market Cap$11.37 million OptionableNot Optionable Beta-0.16 Key ExecutivesMr. David M. Clapper (Age 71)Consultant Comp: $848.92kMr. Joel R. Jung MBA (Age 65)Chief Financial Officer Comp: $461.6kMr. Dominique J. Filloux (Age 60)Chief Operating Officer Comp: $471.6kMr. Thomas PendleburyVP of Sales & MarketingMs. Wendy BowmanVP of HRMs. Joanne LongVP of Corp. ControllerDr. Evgueni V. Skalnyi M.D. (Age 57)VP of Medical Affairs More ExecutivesKey CompetitorsT2 BiosystemsNASDAQ:TTOOInspira Technologies Oxy B.H.N.NASDAQ:IINNSharps TechnologyNASDAQ:STSSAvingerNASDAQ:AVGRInspireMDNYSE:NSPRView All CompetitorsInsiders & InstitutionsLuminus Management LLCBought 316,820 shares on 11/14/2022Ownership: 3.460%View All Institutional Transactions UTRS Stock - Frequently Asked Questions Should I buy or sell Minerva Surgical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Surgical in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UTRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UTRS, but not buy additional shares or sell existing shares. View UTRS analyst ratings or view top-rated stocks. What is Minerva Surgical's stock price forecast for 2023? 2 brokers have issued 1 year price objectives for Minerva Surgical's shares. Their UTRS share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,211.0% from the stock's current price. View analysts price targets for UTRS or view top-rated stocks among Wall Street analysts. How have UTRS shares performed in 2023? Minerva Surgical's stock was trading at $0.2234 at the beginning of the year. Since then, UTRS shares have increased by 70.7% and is now trading at $0.3814. View the best growth stocks for 2023 here. Are investors shorting Minerva Surgical? Minerva Surgical saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 448,500 shares, a decline of 51.2% from the December 31st total of 918,400 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 4.4% of the shares of the company are short sold. View Minerva Surgical's Short Interest. When is Minerva Surgical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our UTRS earnings forecast. How were Minerva Surgical's earnings last quarter? Minerva Surgical, Inc. (NASDAQ:UTRS) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.12. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $12.64 million. Minerva Surgical had a negative net margin of 34.03% and a negative trailing twelve-month return on equity of 51.99%. What guidance has Minerva Surgical issued on next quarter's earnings? Minerva Surgical updated its FY 2022 earnings guidance on Wednesday, December, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50.00 million-$53.00 million, compared to the consensus revenue estimate of $50.85 million. When did Minerva Surgical IPO? (UTRS) raised $100 million in an IPO on Friday, October 22nd 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. What is Minerva Surgical's stock symbol? Minerva Surgical trades on the NASDAQ under the ticker symbol "UTRS." How do I buy shares of Minerva Surgical? Shares of UTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Minerva Surgical's stock price today? One share of UTRS stock can currently be purchased for approximately $0.38. How much money does Minerva Surgical make? Minerva Surgical (NASDAQ:UTRS) has a market capitalization of $11.37 million and generates $52.10 million in revenue each year. How many employees does Minerva Surgical have? The company employs 157 workers across the globe. How can I contact Minerva Surgical? The official website for the company is www.minervasurgical.com. The company can be reached via phone at 855-646-7874 or via email at caroline.corner@westwicke.com. This page (NASDAQ:UTRS) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.